Low dose, short term, triple therapy for helicobacter pylori associated peptic ulcer

To confirm the efficacy and tolerability of a new, low-dose, short-term triple therapy, 31 endoscopically diagnosed cases of peptic ulcer who were helicobacter pylori positive by brush cytology and urease test were inducted into the study. These patients were given lansoprazole 30 mg once a day, clarithromycin 250 mg twice a day and tinidazole 500 mg twice a day for one week only. Endoscopy, urease test and methylene blue test for helicobacter pylori were repeated four weeks after stopping the therapy. Ulcer healed in all the patients while helicobacter was eradicated in 90.3% of patients

Nizatidine and clarithromycin: an effective combination therapy in the treatment of helicobacter pylori associated peptic ulcer

Helicobacter pylori is now accepted as the cause of chronic active type B gastritis and also having a critical role in duodenal ulcer. Most anti-Helicobacter pylori regimens available have drawbacks of adverse effects, prolonged therapy and resistance. The introduction of eradication regimens based on acid suppression in combination with antibiotics are yielding promising results. Combination of Nizatidine 300 mg BID with Clarithromycin 500 mg TID were tried in endoscopically proven Helicobacter Pylori positive patients for 15 days. Endoscopy after 30 days showed healing of 95.2% of ulcers and eradication of Helicobacter pylori infection in the same percentage. It is concluded that this is an effective combination